PSMA-Addition Trial can give access t... - Advanced Prostate...

Advanced Prostate Cancer

21,043 members26,239 posts

PSMA-Addition Trial can give access to Pluvicto for DeNovo or mHSPC

MateoBeach profile image
16 Replies

The range of access to Pluvicto (Lu177-PSMA-617) radionuclide treatment is expanding. Great news. The PSMA-Fore trial recently showed that it iis very beneficial before docetaxel chemotherapy in mCRPC. Now a worldwide trial is exploring it in metastatic hormone sensitive PC, including de novo metastatic. Requirements include no prior chemotherapy (taxane) and generally no ADT or less than 45 days. In my opinion this PSMA-Addition Trial is a great opportunity for those eligible. Thanks to Oliver Sartor and Scott Tagawa et al. Paul/MB

ascopubs.org/doi/10.1200/JC...

clinicaltrials.gov/study/NC...

Written by
MateoBeach profile image
MateoBeach
To view profiles and participate in discussions please or .
Read more about...
16 Replies
MateoBeach profile image
MateoBeach

Have to acknowledge T-A for annnouncing this at the outset in 2021. 👍

MoonRocket profile image
MoonRocket

This is good news. Thanks for sharing. I'll keep my eye on how this progresses. At the moment I'm on mono-enzalutamide thanks to the EMBARK trial.

GP24 profile image
GP24

Yes, a very interesting trial. But the PSMAddition trial [NCT04720157] has already completed accrual.

MateoBeach profile image
MateoBeach in reply to GP24

Didn't know that. Dr. Sartor spoke of it this week at the international conference in Melbourne. Perhaps prelim analysis may be not too far off.

GP24 profile image
GP24 in reply to MateoBeach

The new clinicaltrials.gov website makes it difficult to determine this:

Screenshot clinicaltrials.gov
treedown profile image
treedown

I was excluded from PSMA Addition due to use of Zytiga. The wanted only Lupron. That was year ago.

MoonRocket profile image
MoonRocket in reply to treedown

You can still get in on the PSMA-Subtraction trial: ADT + Zytiga without Lu177.

treedown profile image
treedown in reply to MoonRocket

I got lucky on that one, and I'm in. Trial of 1.

MoonRocket profile image
MoonRocket in reply to treedown

I think I heard of that...Study Numero Uno.

Brysonal profile image
Brysonal

very interesting. I applied for PSMAaddition here in the UK when I first went metastatic but it hadn’t started and with mets popping up everywhere I needed to start my ADT so had to travel to Finland to access it whilst treatment naive and hormone sensitive.

No regrets over using ADT combined with Lu-177 x 3 infusions as my first line treatment ( or indeed with follow g up with 3 x Docetaxel ) and I will follow the PSMA addition trial results with interest.

The OVM-200 vaccine trial I did volunteer for is in phase 1b and published its 3 year stability results today so I continue to follow that one too.

PSA negative still this month and still no idea what helped/ didn’t as I tried it all but Lu-177 up front just seems to make sense and as a symptomless fit man with a deadly silent disease it was a very straight forward treatment worth commuting countries to give it a try. It seems much riskier the sicker you get so I have huge hope for OSMAddition to be a positive trial.

Thanks for sharing

MateoBeach profile image
MateoBeach in reply to Brysonal

So glad to hear your update Brysonal and that you are still doing so well. We are of liike-mind on that. I ask: "What can I do now that may make the difference later, rather than waiting for the disease to advance?" Possibly deflect the trajectory (arrow) of the natural course of progression. Kind regards. Paul

Maxone73 profile image
Maxone73 in reply to Brysonal

New data for OVM-200?? Now, this is good!!

Brysonal profile image
Brysonal in reply to Maxone73

Well news that it’s passed it’s stability tests which they say is an important milestone.

I believe another 24 patients are the plan for this phase of testing which is underway

‘ OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable three years post manufacture – a major milestone for OVM’s lead cancer vaccine, OVM-200 Oxford, UK – 31st January 2024 Press Release – OVM-200 major milestone three year stabilty Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today […]

Maxone73 profile image
Maxone73 in reply to Brysonal

Can I ask: has it worked for you? :-)

Brysonal profile image
Brysonal in reply to Maxone73

No idea but my last scan was clean and PSA undetectable still

I had a lot of beyond SOC treatment so will need the trial to complete to know if it does trigger an immune response.

No regrets taking part in the trial though as no side effects and maybe it works!

Maxone73 profile image
Maxone73 in reply to Brysonal

Well, no SE is a good starting point! 😀

You may also like...

EXPANDED ACCESS FOR Lu-PSMA-617

Expanded access allows a patient with metastatic castration-resistant prostate cancer access to an...

New Trial of Lu-177-PSMA-617 to begin April 30, 2021.

other PSMA-targeted radiotherapy trials in the US)...

Overview of 177Lu PSMA trials

89-5 , https://clinicaltrials.gov/ct2/show/NCT04720157 and the PSMAfore trial for metastatic,...

225Ac-PSMA-I&T works well even after Pluvicto in small trial

225Ac-PSMA-I&T. Surprisingly, no Grade 3 Xerostomia. Phase III trials will likely follow....

VISION trial results of Lu-177-PSMA-617

Novartis has announced 177Lu-PSMA-617 met both primary endpoints, significantly improving overall...